Literature DB >> 10348758

Activities of beta-lactams and macrolides against Helicobacter pylori.

I J Hassan1, R M Stark, J Greenman, M R Millar.   

Abstract

A continuous-culture system (chemostat) was used to study the activities of beta-lactam antimicrobial agents, clarithromycin, and 14-OH-clarithromycin against slowly growing Helicobacter pylori NCTC 11637. H. pylori was grown to steady state before exposure to these antimicrobial agents at x8 the MIC. The bactericidal actions of combinations of amoxicillin and clarithromycin were also studied. Viable counts (numbers of CFU per milliliter) were determined at 2-h intervals for 12 h and at 20 h after the addition of antibiotics. The effects of pH changes (6.5 to 7.4) on the activities of amoxicillin, clarithromycin, and the combination of these against H. pylori NCTC 11637 were also studied. Viable counts following exposure to ampicillin, cefixime, ceftazidime, cefuroxime, cefotaxime, azlocillin, and piperacillin at 20 h showed bacteriostatic activity. Imipenem, meropenem, amoxicillin, clarithromycin, and 14-OH-clarithromycin reduced the viable counts by 3 log10 CFU/ml (>/=99.9% killing). Imipenem was the most rapidly bactericidal against H. pylori NCTC 11637. Results of the pH experiments showed that amoxicillin was bactericidal at pHs 6.5 to 7. 4. Clarithromycin was bactericidal at pH 7.0 to 7.4 but was bacteriostatic at pH 6.5. The combination of amoxicillin and clarithromycin was bactericidal at pHs 6.5 and 7.0. A batch culture (flask system) was also used to investigate 12 strains of H. pylori for their susceptibilities to beta-lactams, clarithromycin, and/or 14-OH-clarithromycin in order to determine whether results from the chemostat model can be reproduced with batch cultures. Results of the chemostat time-kill kinetic study were reproducible in our batch culture flask system. The role of carbapenems in the eradication of H. pylori should be investigated.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10348758      PMCID: PMC89284          DOI: 10.1128/AAC.43.6.1387

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  37 in total

1.  The estimation of the bactericidal power of the blood.

Authors:  A A Miles; S S Misra; J O Irwin
Journal:  J Hyg (Lond)       Date:  1938-11

2.  Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents.

Authors:  M L Grayson; G M Eliopoulos; M J Ferraro; R C Moellering
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-10       Impact factor: 3.267

3.  The true division and death rates of Salmonella typhimurium in the mouse spleen determined with superinfecting phage P22.

Authors:  J Maw; G G Meynell
Journal:  Br J Exp Pathol       Date:  1968-12

Review 4.  In vitro susceptibility testing of Helicobacter pylori to antimicrobial agents: basis for treatment or microbiologists' obsession?

Authors:  Y Glupczynski
Journal:  Zentralbl Bakteriol       Date:  1993-09

5.  The theory and relevance of continuous culture.

Authors:  P Gilbert
Journal:  J Antimicrob Chemother       Date:  1985-01       Impact factor: 5.790

6.  Clarithromycin as monotherapy for eradication of Helicobacter pylori: a randomized, double-blind trial.

Authors:  W L Peterson; D Y Graham; B Marshall; M J Blaser; R M Genta; P D Klein; C W Stratton; J Drnec; P Prokocimer; N Siepman
Journal:  Am J Gastroenterol       Date:  1993-11       Impact factor: 10.864

7.  Intravenous omeprazole/amoxicillin and omeprazole pretreatment in Helicobacter pylori-positive acute peptide ulcer bleeding. A pilot study.

Authors:  R J Adamek; M Freitag; W Opferkuch; G H Rühl; M Wegener
Journal:  Scand J Gastroenterol       Date:  1994-10       Impact factor: 2.423

8.  Additive effect of clarithromycin combined with 14-hydroxy clarithromycin, erythromycin, amoxycillin, metronidazole or omeprazole against Helicobacter pylori.

Authors:  G Cederbrant; G Kahlmeter; C Schalén; C Kamme
Journal:  J Antimicrob Chemother       Date:  1994-12       Impact factor: 5.790

9.  Factors affecting growth and antibiotic susceptibility of Helicobacter pylori: effect of pH and urea on the survival of a wild-type strain and a urease-deficient mutant.

Authors:  J E Sjöström; H Larsson
Journal:  J Med Microbiol       Date:  1996-06       Impact factor: 2.472

10.  Mucosal pharmacokinetics and pilot study of short course of parenteral imipenem in the eradication of Helicobacter pylori.

Authors:  J J Sung; S C Chung; S W Hosking; R C Chan; T K Ling; M Y Yung; A F Cheng; A K Li
Journal:  J Gastroenterol Hepatol       Date:  1995 Jan-Feb       Impact factor: 4.029

View more
  6 in total

1.  Pyridodiazepine amines are selective therapeutic agents for helicobacter pylori by suppressing growth through inhibition of glutamate racemase but are predicted to require continuous elevated levels in plasma to achieve clinical efficacy.

Authors:  Boudewijn L M de Jonge; Amy Kutschke; Joseph V Newman; Michael T Rooney; Wei Yang; Christer Cederberg
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

Review 2.  Vonoprazan-based therapy for Helicobacter pylori eradication: experience and clinical evidence.

Authors:  Yuko Akazawa; Daisuke Fukuda; Yutaka Fukuda
Journal:  Therap Adv Gastroenterol       Date:  2016-09-22       Impact factor: 4.409

3.  In vitro antibacterial and morphological effects of the urushiol component of the sap of the Korean lacquer tree (Rhus vernicifera Stokes) on Helicobacter pylori.

Authors:  Ki Tae Suk; Hyun Soo Kim; Moon Young Kim; Jae Woo Kim; Young Uh; In Ho Jang; Soo Ki Kim; Eung Ho Choi; Myong Jo Kim; Jung Soo Joo; Soon Koo Baik
Journal:  J Korean Med Sci       Date:  2010-02-17       Impact factor: 2.153

4.  A Pilot Randomized Controlled Study of Dexlansoprazole MR-Based Triple Therapy for Helicobacter Pylori Infection.

Authors:  Deng-Chyang Wu; Chao-Hung Kuo; Feng-Woei Tsay; Wen-Hung Hsu; Angela Chen; Ping-I Hsu
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

5.  Factors Affecting the Intraluminal Therapy for Helicobacter pylori Infection.

Authors:  Cheng-Yu Ho; Ting-Wen Liu; Yang-Sheng Lin; Yen-Po Chen; Ming-Jen Chen; Horng-Yuan Wang; Tai-Cherng Liou
Journal:  Microorganisms       Date:  2022-02-11

6.  Efficacy of dexlansoprazole-based triple therapy for Helicobacter pylori infections.

Authors:  Chia-Jung Kuo; Chun-Wei Chen; Puo-Hsien Le; Jun-Te Hsu; Cheng-Yu Lin; Hao-Tsai Cheng; Ming-Yao Su; Chun-Jung Lin; Cheng-Tang Chiu
Journal:  Therap Adv Gastroenterol       Date:  2019-09-05       Impact factor: 4.802

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.